BioCryst Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $78.4M | $-721.8M | $245.8M | $12.9M | $5.1M | $32.0K | $-26.8M | $-14.0M |
| Depreciation & Amortization | — | — | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K |
| Depreciation | $513.0K | $461.0K | — | — | $329.0K | $331.0K | — | — |
| Amortization | $0 | $600.0K | — | — | $0 | $0 | — | — |
| Stock-Based Compensation | $14.7M | $16.0M | $23.8M | $18.6M | $21.3M | $21.4M | $21.3M | $17.2M |
| Net Cash from Operating Activities | $104.3M | $-61.8M | $292.0M | $41.6M | $41.3M | $-27.5M | $-5.2M | $8.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $209.0K | $403.0K | $802.0K | $1.3M | $179.0K | $143.0K | $675.0K | $59.0K |
| Business Acquisitions | $0 | $489.5M | — | — | $0 | $0 | — | — |
| Net Cash from Investing Activities | $-110.1M | $-268.6M | $-83.5M | $13.6M | $29.1M | $27.1M | $17.8M | $8.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-11.2M | $412.6M | $-218.0M | $-58.8M | $-73.7M | $529.0K | $-4.0M | $1.3M |
| Net Change in Cash | $-17.0M | $82.0M | — | — | $-17.0M | $558.0K | $7.3M | $18.9M |
| Free Cash Flow | $104.1M | $-62.2M | $291.2M | $40.3M | $41.1M | $-27.7M | $-5.9M | $8.2M |